Status:
COMPLETED
Safety and Efficacy of a New Therapy as Adjunctive Therapy to Anti-vascular Endothelial Growth Factor (Anti-VEGF) in Subjects With Wet Age-Related Macular Degeneration (AMD)
Lead Sponsor:
Allergan
Conditions:
Choroidal Neovascularization
Age-Related Maculopathy
Eligibility:
All Genders
50+ years
Phase:
PHASE2
Brief Summary
The study will evaluate the safety and efficacy of the intravitreal dexamethasone implant as adjunctive therapy to Anti-VEGF treatment in the study eye of treatment naïve subjects with choroidal neova...
Eligibility Criteria
Inclusion
- 50 years of age or older with active subfoveal choroidal neovascularization (CNV) secondary to AMD
- Central retinal thickness ≥ 300 µm
- Visual acuity between 20/400 and 20/32
- Eligible for Anti-VEGF therapy
Exclusion
- Previous treatment for CNV due to AMD
- High eye pressure
- Glaucoma
- Uncontrolled systemic disease
- Known allergy to the study medications
- Recent eye surgery or injections in the eye
- Female subjects that are of childbearing potential
Key Trial Info
Start Date :
November 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2010
Estimated Enrollment :
44 Patients enrolled
Trial Details
Trial ID
NCT00775411
Start Date
November 1 2008
End Date
April 1 2010
Last Update
September 3 2012
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
San Antonio, Texas, United States
2
Sydney, New South Wales, Australia
3
Manila, Philippines